Recent work demonstrated that afatinib, an approved irreversible electrophilic covalent EGFR/HER2 inhibitor for lung cancer treatment, increased TRIB2 degradation in human acute myeloid leukemia (AML) cancer cells [93], demonstrating for the first time that TRIB2 might be a druggable protein. The gene discussed is EGFR; the disease is lung carcinoma.